

556 Gibraltar Drive Milpitas, CA 95035 T: (800) 832-3200 F: (408) 935-8272

Laboratory Director: Jyotsna S. Shah, Ph.D.

CLIA: 05D0643914 CALIFORNIA: CLF 4033 NPI: 1396837605

www.igenex.com

#### **REFERRING PHYSICIAN**

TEST DOCTOR

#### **TEST PATIENT** DOB: Gender: Accession: Patient ID:

Collected: Received: Reported: Reprinted: Amended: Corrected:

# **BORRELIOSIS - Lyme Disease**

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
Lyme ImmunoBlot IgG	Serum			
IGX Criteria:		Positive		
CDC/NYS Criteria:		Negative		
(REVISED REPORT: EFFECTIVE AP	RIL 10, 2019]			
Lyme ImmunoBlot IgG detects antiboo species	lies to B. burgdo	orferi strains ar	nd	

Band (kDa)	18	23*	28	30	31*	34*	39*	41*	45	58	66	93*
Intensity	-	+	-	-	-	-	-	+	-	-	-	+

Band Intensity: Positive: + to ++++, Indeterminate: Ind, Negative: (-)

### INTERPRETATION **IGX CRITERIA** 2 or more of the starred Positive bands are present (+): 23\*, 31\*, 34\*, 39\*, 41\*, 93\* kDa Does not meet IGX criteria for a

### **CDC/NYS CRITERIA**

5 or more of the following bands are present (+): 18, 23\*, 28, 30, 39\*, 41\*, 45, 58, 66, 93\* kDa

Negative

positive.

### Does not meet CDC/NYS criteria for a positive.

#### LIMITATION: Bands 31\* and 34\* kDa are present in Lyme vaccinated patients. Viral antibodies cross react with the 93 kDa antigen.

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.

556 Gibraltar Drive Milpitas, CA 95035 T: (800) 832-3200 F: (408) 935-8272

www.igenex.com

Laboratory Director: Jyotsna S. Shah, Ph.D.

 CLIA:
 05D0643914

 CALIFORNIA:
 CLF 4033

 NPI:
 1396837605

# TEST **SPECIMEN** RESULT **REFERENCE RANGE** UNITS LYME IMMUNOBLOT IGG SPECIATION B. burgdorferi US(genus) Positive Serum B. burgdorferi US spp Serum Negative BbSs: Borrelia burgdorferi sensu stricto includes but not limited to B. burgdorferi B31 and B. burgdorferi 29 BbSI: Borrelia burgdorferi sensu lato includes but not limited to B. mayonii and B. californiensis. B. burgdorferi European(genus) Serum Negative B. burgdorferi European Spp Serum Negative Borrelia burgdorferi European species include but not limited to B. afzelii, B. garinii, B. spielmanii and B. valaisiana. B. burgdorferi Species Serum Positive B. burgdorferi species include but not limited to Bb B31, Bb 297, mayonii, B. californiensis, B. afzelii, B. garinii, B. spielmanii and B. valaisian

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.



TEST

\*\*\*

556 Gibraltar Drive Milpitas, CA 95035 T: (800) 832-3200 F: (408) 935-8272

www.igenex.com

**SPECIMEN** 

Laboratory Director: Jyotsna S. Shah, Ph.D.

 CLIA:
 05D0643914

 CALIFORNIA:
 CLF 4033

 NPI:
 1396837605

**REFERENCE RANGE** 

UNITS

Lyme ImmunoBlot IgM	Serum
IGX Criteria:	
CDC/NYS Criteria:	

Positive Positive

RESULT

[REVISED REPORT: EFFECTIVE APRIL 10, 2019]

Lyme ImmunoBlot IgM detects antibodies to B. burgdorferi strains and species

Band (kDa)	31*	34*	39*	41*	93
Intensity	+	+	-	+	IND

Band Intensity: Positive: + to ++++, Indeterminate: Ind, Negative: (-)

INTERPRETATION	IGX CRITERIA	CDC/NYS CRITERIA
Positive	2 or more of the starred bands are present (+): 23*, 31*, 34*, 39*, 41* kDa	2 or more of the following bands are present (+): 23*, 39*, 41* kDa
Negative	Does not meet IGX criteria for a positive.	Does not meet CDC/NYS criteria for a positive.

**LIMITATION:** Bands 31\* and 34\* kDa are present in Lyme vaccinated patients. Viral antibodies cross react with the 93 kDa antigen.

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.

Ioz	<b>X</b> ®
	IGeneX Inc.

556 Gibraltar Drive Milpitas, CA 95035 T: (800) 832-3200 F: (408) 935-8272 Laboratory Director: Jyotsna S. Shah, Ph.D.

CLIA: 05D0643914 CALIFORNIA: CLF 4033 NPI: 1396837605

ww	W.I0	len	ex.(	com

TEST	SPECIMEN	RESULT	REFERENCE RANGE	UNITS
LYME IMMUNOBLOT IGM SPECIA	TION			
B. burgdorferi US(genus)	Serum	Positive		
B. burgdorferi US Spp	Serum	Negative		
BbSs: Borrelia burgdorferi sensu stricto inclu		•		
B. burgdorferi B31 and B. burgdorferi 29				
BbSI: Borrelia burgdorferi sensu lato include	s but not limited to	B.		
mayonii and B. californiensis.		2.		
B. burgdorferi European(genus)	Serum	Positive		
B. burgdorferi European Spp	Serum	Negative		
Borrelia burgdorferi European species incluc	le but not limited to	В.		
afzelii, B. garinii, B. spielmanii and B. valaisia	ana.			
B. burgdorferi Species	Serum	Positive		
B. burgdorferi species include but not limited	to Bb B31, Bb 297	9		
mayonii, B. californiensis, B. afzelii, B. garini	i, B. spielmanii and			
B. valaisian				
Lyme Multiplex PCR - Serum				
Serum - Genomic	Serum	Negative		
Serum - Plasmid	Serum	Negative		
Lyme Multiplex PCR -Whole Blood				
Whole blood - Genomic	W blood	Negative		
Whole blood - Plasmid	W blood	Negative		

# **End of Report**

Testing performed at IGeneX 556 Gibraltar Drive Milpitas CA 95035 (800) 832-3200

Diagnosis should not be based on laboratory results alone. Results should be interpreted in conjunction with clinical symptoms and patient history.

NOTE: Western Blots, ImmunoBlots, Lyme Dot Blot, Epitope, PCR, IFA, FISH, C. pneumoniae IgG/IgA, CD57, IGXSpot, Broad Coverage Antibody, COVID-19 Test - These tests were developed and their performance characteristics determined by IGeneX, Inc. They have not been cleared or approved by the FDA. The FDA has determined that such approval is not necessary. These tests are used for clinical purposes and should not be regarded as investigational or for research. IGeneX, Inc. is licensed by CMS and NYS to perform high complexity clinical laboratory testing.